Refine
Has Fulltext
- yes (496)
Is part of the Bibliography
- no (496)
Keywords
- prostate cancer (22)
- radical prostatectomy (14)
- Heavy Ion Experiments (13)
- Hadron-Hadron scattering (experiments) (11)
- bladder cancer (11)
- growth (6)
- integrins (6)
- Prostate cancer (5)
- Heavy-ion collision (4)
- chemotherapy (4)
- curcumin (4)
- external beam radiotherapy (4)
- invasion (4)
- metastatic prostate cancer (4)
- mortality (4)
- sulforaphane (4)
- 177Lu-PSMA-617 (3)
- Adenocarcinoma (3)
- FFLU (3)
- PSMA (3)
- Squamous cell carcinoma (3)
- Variant histology (3)
- primary prostate cancer (3)
- proliferation (3)
- survival (3)
- systematic biopsy (3)
- Bladder cancer (2)
- CD44 (2)
- CSM (2)
- Cancer-specific mortality (2)
- Epidemiology and End Results (2)
- Gleason score (2)
- HoLEP (2)
- Melanoma (2)
- NCCN (2)
- PSA (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Penile cancer (2)
- Radical prostatectomy (2)
- SCC (2)
- Surveillance (2)
- Urethral cancer (2)
- adhesion (2)
- cancer specific survival (2)
- cancer-specific mortality (2)
- concordance (2)
- contemporary (2)
- functional outcome (2)
- fusion biopsy (2)
- immunohistochemistry (2)
- intermediate risk (2)
- kidney cancer (2)
- localized prostate cancer (2)
- lymph node dissection (2)
- mTOR (2)
- other-cause mortality (2)
- outcomes (2)
- overall survival (2)
- radical cystectomy (2)
- radical prostatecomy (2)
- renal cell cancer (2)
- resistance (2)
- salvage radical prostatectomy (2)
- tumor growth (2)
- upgrading (2)
- urological cancer (2)
- very high risk (2)
- 223Radium-dichloride (1)
- AKT-mTOR pathway (1)
- ASAP (1)
- Acute kidney injury (1)
- Akt-mTOR pathway (1)
- Akt-mTOR signaling (1)
- Anticoagulation (1)
- Artificial intelligence (1)
- Awareness campaign (1)
- BMI (1)
- BPH (1)
- BPO (1)
- Bleeding (1)
- CDK-cyclin axis (1)
- CRPC (1)
- Cancer check up (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Checkpoint inhibitor (1)
- Chemoprevention (1)
- Clavien–Dindo classification (1)
- Complications (1)
- Cystatin C (1)
- Cytoreductive nephrectomy (1)
- Dietary HDAC inhibitor (1)
- Downgrading (1)
- D’Amico classification (1)
- EBRT (1)
- Electroweak interaction (1)
- External beam radiotherapy (1)
- Extraprostatic (1)
- Functional outcomes (1)
- GFR (1)
- Geographical disparities (1)
- Gleason Grade group (1)
- Gleason Score (1)
- Gleason grade group (1)
- Gleason upgrading (1)
- HDAC (1)
- HOLEP (1)
- Hematologic adverse events (1)
- Hematotoxicity (1)
- High-risk prostate cancer (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- Holmium laser enucleation (1)
- IGF-1 (1)
- IHC (1)
- IPSS (1)
- Immunotherapy (1)
- Incidence rate (1)
- Incidental prostate cancer (1)
- Inferior vena cava thrombus (1)
- Intermediate-risk (1)
- Keap1-Nrf2 (1)
- Lee type, functional outcome (1)
- Lee-type (1)
- Lepton-Nucleon Scattering (experiments) (1)
- Local therapy (1)
- Locally advanced (1)
- Long-term continence (1)
- Machine learning (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Metastatic renal cell carcinoma (1)
- Mortality (1)
- Multiparametric MRI (1)
- NIS (1)
- NVBP (1)
- Nephrectomy (1)
- NeuroSAFE (1)
- Nivolumab (1)
- Non-urothelial (1)
- OR time (1)
- ORP (1)
- Oligometastatic (1)
- Organ-confined (1)
- PAD-test (1)
- PD-1 inhibitor (1)
- PROM (1)
- PSA screening (1)
- PSA-Screening (1)
- Positron-emission tomography (1)
- Preventive medicine (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Prostate-specific membrane antigen (1)
- Prostatic neoplasms (1)
- Prävention (1)
- QOL (1)
- RARP (1)
- ROS (1)
- Race (1)
- Radical cystectomy (1)
- Radiomics (1)
- Radiotherapy (1)
- Region (1)
- Renal cell carcinoma (1)
- Renal vein thrombus (1)
- Robotic-assisted radical prostatectomy (1)
- SEER (1)
- Salvage therapy (1)
- Single positive core biopsy (1)
- Social differences (1)
- Stage at presentation (1)
- Sulphoraphane (1)
- Systemic therapy (1)
- TUR-P (1)
- Time trend (1)
- Transfusion (1)
- Transitional cell carcinoma (1)
- Transurethral resection of the prostate (1)
- Treatment rates (1)
- Upgrading (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Urologic tumors (1)
- Urothelial cancer (1)
- Vorsorgeuntersuchung (1)
- adjuvant chemotherapy (1)
- amygdalin (1)
- antibiotic treatment (1)
- apex (1)
- bioavailability (1)
- biopsy (1)
- biopsy cores (1)
- biopsy naïve (1)
- blood loss (1)
- bone barrow (1)
- buccal mucosal graft urethroplasty (1)
- cabazitaxel (1)
- cabozantinib (1)
- cancer-specific survival (1)
- castration resistance (1)
- catheter (1)
- catheter removal (1)
- cdk (1)
- cell cycling (1)
- cell growth (1)
- cellular heterogeneity (1)
- chemoprotection (1)
- chemoresistance (1)
- chemotaxis (1)
- clinical node positive (1)
- colon cancer (1)
- complementary/alternative medicine (CAM) (1)
- complication (1)
- complications (1)
- consensus classification (1)
- correlation (1)
- cost analysis (1)
- cyclins (1)
- deferred treatment (1)
- delayed treatment (1)
- diffuse marrow involvement (1)
- docetaxel (1)
- double negative (1)
- downgrading (1)
- drug resistance (1)
- early continence (1)
- elderly (1)
- endothelial cells (1)
- epididymitis (1)
- ethnicity (1)
- everolimus (1)
- heart (1)
- hepatocellular carcinoma (1)
- high risk (1)
- high-risk (1)
- histological outcomes (1)
- histone deacetylase (1)
- human (1)
- incontinence (1)
- infection (1)
- inverse stage migration (1)
- kidney (1)
- length of stay (1)
- light irradiation (1)
- liver (1)
- local treatment (1)
- low risk (1)
- lung cancer (1)
- lymph node metastases (1)
- mCRPC (1)
- mechanistic target of rapamycin (mTOR) (1)
- membranous urethra (1)
- metastasis (1)
- metastatic castration-resistant prostate cancer (1)
- metastatic urethral cancer (1)
- mid-term urinary continence (1)
- molecular subtyping (1)
- mpMRI (1)
- mtor (1)
- multiparametric magnetic resonance imaging (1)
- neoadjuvant chemotherapy (1)
- nerve-sparing (1)
- nerve-sparing surgery (1)
- neurovascular bundle preservation (1)
- non-organ confined stage (1)
- olive mill wastewater (OMWW) (1)
- open (1)
- other cause mortality (1)
- overtreatment (1)
- oxidative stress (1)
- pad-test (1)
- patient-reported outcome measure (1)
- perioperative outcome (1)
- post-radiotherapy recurrence (1)
- predictor (1)
- prehabilitation (1)
- prognosis (1)
- prostate neoplasm (1)
- prostate volume (1)
- prostate-specific antigen (1)
- race (1)
- race/ethnicity disparities (1)
- radiation (1)
- renal cell carcinoma (1)
- repeat biopsy (1)
- resistant cell lines (1)
- risk score (1)
- robotic-assisted (1)
- second-line (1)
- secondary cancer (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- single-cell proteomics (1)
- stage (1)
- suprapubic catheter (1)
- surgical complications (1)
- surgical margin (1)
- targeted biopsy (1)
- temsirolimus (1)
- temsirolimus-resistance (1)
- transrectal prostate biopsy (1)
- transurethral catheter (1)
- tumor adhesion (1)
- tumor migration (1)
- tumor proliferation (1)
- tumor weight (1)
- tyrosine kinase inhibitors (1)
- upstaging (1)
- urethral stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- valproic acid (1)
- very high-risk (1)
- waiting time (1)
- Öffentlichkeit (1)
Institute
- Physik (412)
- Frankfurt Institute for Advanced Studies (FIAS) (373)
- Informatik (358)
- Medizin (84)
- Biowissenschaften (1)
- Informatik und Mathematik (1)
The measurements of the inclusive J/ψ yield at midrapidity (|y|<0.9) and forward rapidity (2.5 <y< 4) in Pb−Pb collisions at sNN−−−√=5.02 TeV with the ALICE detector at the LHC are reported. The inclusive J/ψ production yields and nuclear modification factors, RAA, are measured as a function of the collision centrality, J/ψ transverse momentum (pT), and rapidity. The J/ψ average transverse momentum and squared transverse momentum (⟨pT⟩ and ⟨p2T⟩) are evaluated as a function of the centrality at midrapidity. Compared to the previous ALICE publications, here the entire Pb−Pb collisions dataset collected during the LHC Run 2 is used, which improves the precision of the measurements and extends the pT coverage. The pT-integrated RAA shows a hint of an increasing trend towards unity from semicentral to central collisions at midrapidity, while it is flat at forward rapidity. The pT-differential RAA shows a strong suppression at high pT with less suppression at low pT where it reaches a larger value at midrapidity compared to forward rapidity. The ratio of the pT-integrated yields of J/ψ to those of D0 mesons is reported for the first time for the central and semicentral event classes at midrapidity. Model calculations implementing charmonium production via the coalescence of charm quarks and antiquarks during the fireball evolution (transport models) or in a statistical approach with thermal weights are in good agreement with the data at low pT. At higher pT, the data are well described by transport models and a model based on energy loss in the strongly-interacting medium produced in nuclear collisions at the LHC.
Introduction and Objectives: Surgical techniques such as preservation of the full functional-length of the urethral sphincter (FFLU) have a positive impact on postoperative continence rates. Thereby, data on very early continence rates after radical prostatectomy (RP) are scarce. The aim of the present study was to analyze very early continence rates in patients undergoing FFLU during RP.
Materials and Methods: Very early-continence was assessed by using the PAD-test within 24 h after removal of the transurethral catheter. The PAD-test is a validated test that measures the amount of involuntary urine loss while performing predefined physical activities within 1 h (e.g., coughing, walking, climbing stairs). Full continence was defined as a urine loss below 1 g. Mild, moderate, and severe incontinence was defined as urine loss of 1–10 g, 11–50 g, and >50 g, respectively.
Results: 90 patients were prospectively analyzed. Removal of the catheter was performed on the 6th postoperative day. Proportions for no, mild, moderate and severe incontinence were 18.9, 45.5, 20.0, and 15.6%, respectively. In logistic regression younger age was associated with significant better continence (HR 2.52, p = 0.04), while bilateral nerve-sparing (HR 2.56, p = 0.057) and organ-confined tumor (HR 2.22, p = 0.078) showed lower urine loss, although the effect was statistically not significant. In MVA, similar results were recorded.
Conclusion: Overall, 64.4% of patients were continent or suffered only from mild incontinence at 24 h after catheter removal. In general, reduced urine loss was recorded in younger patients, patients with organ-confined tumor and in patients with bilateral nerve sparing. Severe incontinence rates were remarkably low with 15.6%.
Objective: To investigate the value of standard [digital rectal examination (DRE), PSA] and advanced (mpMRI, prostate biopsy) clinical evaluation for prostate cancer (PCa) detection in contemporary patients with clinical bladder outlet obstruction (BOO) scheduled for Holmium laser enucleation of the prostate (HoLEP).
Material and Methods: We retrospectively analyzed 397 patients, who were referred to our tertiary care laser center for HoLEP due to BOO between 11/2017 and 07/2020. Of those, 83 (20.7%) underwent further advanced clinical PCa evaluation with mpMRI and/or prostate biopsy due to elevated PSA and/or lowered PSA ratio and/or suspicious DRE. Logistic regression and binary regression tree models were applied to identify PCa in BOO patients.
Results: An mpMRI was conducted in 56 (66%) of 83 patients and revealed PIRADS 4/5 lesions in 14 (25%) patients. Subsequently, a combined systematic randomized and MRI-fusion biopsy was performed in 19 (23%) patients and revealed in PCa detection in four patients (5%). A randomized prostate biopsy was performed in 31 (37%) patients and revealed in PCa detection in three patients (4%). All seven patients (9%) with PCa detection underwent radical prostatectomy with 29% exhibiting non-organ confined disease. Incidental PCa after HoLEP (n = 76) was found in nine patients (12%) with advanced clinical PCa evaluation preoperatively. In univariable logistic regression analyses, PSA, fPSA ratio, and PSA density failed to identify patients with PCa detection. Conversely, patients with a lower International Prostate Symptom Score (IPSS) and PIRADs 4/5 lesion in mpMRI were at higher risk for PCa detection. In multivariable adjusted analyses, PIRADS 4/5 lesions were confirmed as an independent risk factor (OR 9.91, p = 0.04), while IPSS did not reach significance (p = 0.052).
Conclusion: In advanced clinical PCa evaluation mpMRI should be considered in patients with elevated total PSA or low fPSA ratio scheduled for BOO treatment with HoLEP. Patients with low IPSS or PIRADS 4/5 lesions in mpMRI are at highest risk for PCa detection. In patients with a history of two or more sets of negative prostate biopsies, advanced clinical PCa evaluation might be omitted.
Objective: To investigate temporal trends in prostate cancer (PCa) radical prostatectomy (RP) candidates.
Materials and Methods: Patients who underwent RP for PCa between January 2014 and December 2019 were identified form our institutional database. Trend analysis and logistic regression models assessed RP trends after stratification of PCa patients according to D'Amico classification and Gleason score. Patients with neoadjuvant androgen deprivation or radiotherapy prior to RP were excluded from the analysis.
Results: Overall, 528 PCa patients that underwent RP were identified. Temporal trend analysis revealed a significant decrease in low-risk PCa patients from 17 to 9% (EAPC: −14.6%, p < 0.05) and GS6 PCa patients from 30 to 14% (EAPC: −17.6%, p < 0.01). This remained significant even after multivariable adjustment [low-risk PCa: (OR): 0.85, p < 0.05 and GS6 PCa: (OR): 0.79, p < 0.001]. Furthermore, a trend toward a higher proportion of intermediate-risk PCa undergoing RP was recorded.
Conclusion: Our results confirm that inverse stage migration represents an ongoing phenomenon in a contemporary RP cohort in a European tertiary care PCa center. Our results demonstrate a significant decrease in the proportion of low-risk and GS6 PCa undergoing RP and a trend toward a higher proportion of intermediate-risk PCa patients undergoing RP. This indicates a more precise patient selection when it comes to selecting suitable candidates for definite surgical treatment with RP.
Objective: This study aims to evaluate catheter management in acute epididymitis (AE) patients requiring inpatient treatment and risk factors predicting severity of disease.
Material and Methods: Patients with diagnosed AE and inpatient treatment between 2004 and 2019 at the University Hospital Frankfurt were analyzed. A risk score, rating severity of AE, including residual urine > 100 ml, fever > 38.0°C, C-reactive protein (CRP) > 5 mg/dl, and white blood count (WBC) > 10/nl was introduced.
Results: Of 334 patients, 107 (32%) received a catheter (transurethral (TC): n = 53, 16%, suprapubic (SPC): n = 54, 16%). Catheter patients were older, exhibited more comorbidities, and had higher CRP and WBC compared with the non-catheter group (NC). Median length of stay (LOS) was longer in the catheter group (7 vs. 6 days, p < 0.001), whereas necessity of abscess surgery and recurrent epididymitis did not differ. No differences in those parameters were recorded between TC and SPC. According to our established risk score, 147 (44%) patients exhibited 0–1 (low-risk) and 187 (56%) 2–4 risk factors (high-risk). In the high-risk group, patients received a catheter significantly more often than with low-risk (TC: 22 vs. 9%; SPC: 19 vs. 12%, both p ≤ 0.01). Catheter or high-risk patients exhibited positive urine cultures more frequently than NC or low-risk patients. LOS was comparable between high-risk patients with catheter and low-risk NC patients.
Conclusion: Patients with AE who received a catheter at admission were older, multimorbid, and exhibited more severe symptoms of disease compared with the NC patients. A protective effect of catheters might be attributable to patients with adverse risk constellations or high burden of comorbidities. The introduced risk score indicates a possibility for risk stratification.
Up to 50% of patients initially treated for prostate cancer in a curative intent experience biochemical recurrence, possibly requiring adjuvant treatment. However, salvage treatment decisions, such as lymph node dissection or radiation therapy, are typically based on prostate specific antigen (PSA) recurrence. Importantly, common imaging modalities (e.g., computed tomography [CT], magnetic resonance imaging, and bone scan) are limited and the detection of recurrent disease is particularly challenging if PSA is low. Prostate specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) is a novel and promising imaging modality which aims to overcome the incapability of early identification of distant and regional metastases. Within this review, we summarize the current evidence related to PSMA-PET/CT in prostate cancer men diagnosed with biochemical recurrence after local treatment with curative intent. We discuss detection rates of PSMA-PET/CT stratified by PSA-levels and its impact on clinical decision making. Furthermore, we compare different imagefusion techniques such as PSMA-PET vs. F-/C-Choline-PET scans vs. PSMA-single photon emission computed tomography/CT. Finally, we touch upon the contemporary role of radio-guided-PSMA salvage lymphadenectomy.
Objective: We aimed to assess the correlation between serum prostate-specific antigen (PSA) and tumor burden in prostate cancer (PCa) patients undergoing radical prostatectomy (RP), because estimation of tumor burden is of high value, e.g., in men undergoing RP or with biochemical recurrence after RP. Patients and Methods: From January 2019 to June 2020, 179 consecutive PCa patients after RP with information on tumor and prostate weight were retrospectively identified from our prospective institutional RP database. Patients with preoperative systemic therapy (n=19), metastases (cM1, n=5), and locally progressed PCa (pT4 or pN1, n=50) were excluded from analyses. Histopathological features, including total weight of the prostate and specific tumor weight, were recorded by specialized uro-pathologists. Linear regression models were performed to evaluate the effect of PSA on tumor burden, measured by tumor weight after adjustment for patient and tumor characteristics. Results: Overall, median preoperative PSA was 7.0 ng/ml (interquartile range [IQR]: 5.41–10) and median age at surgery was 66 years (IQR: 61-71). Median prostate weight was 34 g (IQR: 26–46) and median tumor weight was 3.7 g (IQR: 1.8–7.1), respectively. In multivariable linear regression analysis after adjustment for patients and tumor characteristics, a significant, positive correlation could be detected between preoperative PSA and tumor weight (coefficient [coef.]: 0.37, CI: 0.15–0.6, p=0.001), indicating a robust increase in PSA of almost 0.4 ng/ml per 1g tumor weight. Conclusion: Preoperative PSA was significantly correlated with tumor weight in PCa patients undergoing RP, with an increase in PSA of almost 0.4 ng/ml per 1 g tumor weight. This might help to estimate both tumor burden before undergoing RP and in case of biochemical recurrence.
Objective: Many patients with localized prostate cancer (PCa) do not immediately undergo radical prostatectomy (RP) after biopsy confirmation. The aim of this study was to investigate the influence of “time-from-biopsy-to- prostatectomy” on adverse pathological outcomes.
Materials and Methods: Between January 2014 and December 2019, 437 patients with intermediate- and high risk PCa who underwent RP were retrospectively identified within our prospective institutional database. For the aim of our study, we focused on patients with intermediate- (n = 285) and high-risk (n = 151) PCa using D'Amico risk stratification. Endpoints were adverse pathological outcomes and proportion of nerve-sparing procedures after RP stratified by “time-from-biopsy-to-prostatectomy”: ≤3 months vs. >3 and < 6 months. Medians and interquartile ranges (IQR) were reported for continuously coded variables. The chi-square test examined the statistical significance of the differences in proportions while the Kruskal-Wallis test was used to examine differences in medians. Multivariable (ordered) logistic regressions, analyzing the impact of time between diagnosis and prostatectomy, were separately run for all relevant outcome variables (ISUP specimen, margin status, pathological stage, pathological nodal status, LVI, perineural invasion, nerve-sparing).
Results: We observed no difference between patients undergoing RP ≤3 months vs. >3 and <6 months after diagnosis for the following oncological endpoints: pT-stage, ISUP grading, probability of a positive surgical margin, probability of lymph node invasion (LNI), lymphovascular invasion (LVI), and perineural invasion (pn) in patients with intermediate- and high-risk PCa. Likewise, the rates of nerve sparing procedures were 84.3 vs. 87.4% (p = 0.778) and 61.0% vs. 78.8% (p = 0.211), for intermediate- and high-risk PCa patients undergoing surgery after ≤3 months vs. >3 and <6 months, respectively. In multivariable adjusted analyses, a time to surgery >3 months did not significantly worsen any of the outcome variables in patients with intermediate- or high-risk PCa (all p > 0.05).
Conclusion: A “time-from-biopsy-to-prostatectomy” of >3 and <6 months is neither associated with adverse pathological outcomes nor poorer chances of nerve sparing RP in intermediate- and high-risk PCa patients.
Introduction: MRI-targeted biopsy (TB) increases overall prostate-cancer (PCa) detection-rates and decreases the risk of insignificant PCa detection. However, the impact of these findings on the definite pathology after radical prostatectomy (RP) is under debate.
Materials and Methods: Between 01/2014 and 12/2018, 366 patients undergoing prostate biopsy and RP were retrospectively analyzed. The correlation between biopsy Gleason-score (highest Gleason-score in a core) and the RP Gleason-score in patients undergoing systematic biopsy (SB-group) (n = 221) or TB+SB (TB-group, n = 145) was tested using the ISUP Gleason-group grading (GGG, scale 1–5). Sub analyses focused on biopsy GGG 1 and GGG ≥ 2.
Results: Proportions of biopsy GGG 1–5 in the SB-group and TB-group were 24.4, 37.6, 19, 10.9, 8.1% and 13.8, 43.4, 24.2, 13.8, 4.8%, respectively (p = 0.07). Biopsy and pathologic GGG were concordant in 108 of 221 (48.9%) in SB- and 74 of 145 (51.1%) in TB-group (p = 0.8). Gleason upgrading was recorded in 33.5 and 31.7% in SB- vs. TB-group (p = 0.8). Patients with biopsy GGG 1 undergoing RP showed an upgrading in 68.5%(37/54) in SB- and 75%(15/20) in TB-group (p = 0.8). In patients with biopsy GGG ≥ 2 concordance increased for both biopsy approaches (54.5 vs. 55.2% for SB- vs. TB-group, p = 0.9).
Discussion: Irrespective of differences in PCa detection-rates between TB- and SB-groups, no significant differences in GGG concordance and upgrading between patients of both groups undergoing biopsy, followed by RP, were recorded. Concordance rates increased in men with biopsy GGG ≥ 2. TB seems to detect more patients with PCa without a difference in concordance with final pathology.
hintergrund: Männer in Deutschland sterben früher als Frauen und nehmen weniger häufig Krebsvorsorgeuntersuchungen wahr.
Fragestellung: Ziel war die prospektive Evaluation einer „Movember-Gesundheitsinitiative“ am Universitätsklinikum Frankfurt (UKF) im November 2019.
Methoden: Im Rahmen der „Movember-Gesundheitsinitiative“ wurde allen männlichen Mitarbeitern des UKF ab dem 45. Lebensjahr und bei erstgradiger familiärer Vorbelastung eines Prostatakarzinoms ab dem 40. Lebensjahr im November 2019 gemäß S3-Leitlinien der Deutschen Gesellschaft für Urologie (DGU) eine Prostatakarzinom-Vorsorgeuntersuchung angeboten.
Ergebnisse: Insgesamt nahmen 14,4 % der Mitarbeiter teil. Eine familiäre Vorbelastung gaben insgesamt 14,0 % Teilnehmer an. Das mediane Alter betrug 54 Jahre. Der mediane PSA(prostataspezifisches Antigen)-Wert lag bei 0,9 ng/ml, der mediane PSA-Quotient bei 30 %. Bei 5 % (n = 6) zeigte sich ein suspekter Tastbefund in der DRU (digital-rektale Untersuchung). Nach Altersstratifizierung (≤ 50 vs. > 50 Lebensjahre) zeigten sich signifikante Unterschiede im medianen PSA-Wert (0,7 ng/ml vs. 1,0 ng/ml, p < 0,01) und der bereits zuvor durchgeführten urologischen Vorsorge (12,1 vs. 42,0 %, p < 0,01). Vier Teilnehmer (3,3 %) zeigten erhöhte Gesamt-PSA-Werte. Bei 32,2 % der Teilnehmer zeigte sich mindestens ein kontrollbedürftiger Befund. Insgesamt wurden 6 Prostatabiopsien durchgeführt. Hierbei zeigte sich in einem Fall ein intermediate-risk Prostatakarzinom (Gleason 3 + 4, pT3a, pPn1, pNx, R0).
Schlussfolgerungung: Im Rahmen der UKF-Movember-Gesundheitsinitiative 2019 konnten durch ein Vorsorgeangebot 121 Männer für eine Prostatakrebs-Vorsorge inklusive PSA-Testung gewonnen werden. Auffällige/kontrollbedürftige Befunde zeigten sich bei 32,2 %. Bei einem Mitarbeiter wurde ein therapiebedürftiges Prostatakarzinom entdeckt und therapiert.